Semaglutide vs. tirzepatide: how the two leading drugs compare

If you have started reading about medical weight loss, you have run into two names over and over: semaglutide and tirzepatide. They are the active ingredients behind the brands most people recognize. Semaglutide is sold as Wegovy (for weight loss) and Ozempic (for type 2 diabetes). Tirzepatide is sold as Zepbound (for weight loss) and Mounjaro (for diabetes). They are related, they are not identical, and the differences matter when you and a clinician are choosing between them.

The mechanism is the core difference

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone called glucagon-like peptide-1, which slows stomach emptying, blunts appetite, and helps regulate blood sugar. Tirzepatide does that too, but it is a dual agonist: it also activates the GIP receptor (glucose-dependent insulinotropic polypeptide). The working theory is that hitting both pathways produces a stronger effect on appetite and metabolism. You can read a plain overview of how GLP-1 drugs work at Mayo Clinic. If you want the bigger picture of how these drugs reshaped the field, see our overview of medical weight loss in the GLP-1 era.

What the trials actually showed

The headline numbers come from large randomized trials. In the STEP 1 trial, people on semaglutide lost an average of about 15 percent of body weight over 68 weeks. In the SURMOUNT-1 trial, people on the highest dose of tirzepatide lost roughly 21 percent over 72 weeks. Those were separate studies with different participants, so the comparison is not perfectly apples to apples. But the direction is consistent: on average, tirzepatide tends to produce more weight loss than semaglutide. A head-to-head diabetes trial, SURPASS-2, pointed the same way on blood sugar and weight.

Averages hide a lot, though. Plenty of people do beautifully on semaglutide, and some respond better to it than to tirzepatide. Biology is individual, and the right drug is the one that works for your body with side effects you can live with. It is also worth remembering that the trial participants ate, exercised, and were coached under study conditions; real-world results vary, and the medication is a tool that works best alongside changes in food and activity, not a replacement for them.

How you take them is nearly identical

For practical purposes, the two drugs feel similar day to day. Both are once-weekly injections you give yourself with a small needle, usually in the abdomen, thigh, or upper arm, and both start at a low dose that steps up over months. That gradual ramp, called titration, is built into both products to limit side effects, and it means neither drug delivers its full effect in the first few weeks. An oral form of semaglutide exists for diabetes, but the high-dose injections are what the weight-loss data above are based on. If you dislike needles, that is a reasonable thing to raise with a prescriber, though for most people the injection is far less of an ordeal than they expect.

Side effects look broadly similar

Both drugs share the same main side effects, and they come from the same place: a slowed digestive system. Nausea, constipation, diarrhea, and reflux are the usual complaints, and they are worst when you first start or step up a dose. For most people these ease over a few weeks. If nausea is your sticking point, our guide to managing GLP-1 nausea covers what tends to help. Serious risks are rare but real, which is why both carry warnings and require a clinician's oversight. Nothing here is dosing advice; that conversation belongs with a licensed prescriber who knows your history.

Cost and access are often the deciding factor

On paper you might just pick the more effective drug. In practice, price and insurance frequently make the choice for you. Both brands carry high list prices, coverage varies wildly by plan, and supply has been uneven. Some people end up on whichever one their insurance will actually cover, or whichever is in stock. We break down the money side in our piece on GLP-1 cost and insurance.

How to think about the choice

If maximum average weight loss is the priority and cost is not a barrier, the trial data lean toward tirzepatide. If you tolerate semaglutide well, have coverage for it, or your clinician has a specific reason to prefer it, it remains a strong, well-studied option. The honest takeaway: these are two excellent tools, tirzepatide has a modest edge on average weight loss in the data we have, and the best one for you depends on your response, your tolerance, and what you can actually get and afford. Bring the trade-offs to a licensed clinician and decide together.

Related reading: Compounded vs. brand-name semaglutide: what to know.